Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
MWN-AI** Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) has achieved notable recognition at the Cardiovascular Research Technologies (CRT) 2026 Meeting, set to occur from March 7-10 in Washington, DC. The company announced that Dr. Nikola Cesarovic will present a groundbreaking abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,” during the Top Abstract Session on March 7. This six-minute presentation will showcase early data on a pioneering RF-based method aimed at selectively disrupting peripheral nerve activity through a transvascular approach.
Dr. Cesarovic's findings reflect the company's commitment to advancing precision nerve-targeted therapies. Autonomix’s technology employs a sophisticated catheter-based microchip sensing array, designed to differentiate neural signals with exceptional sensitivity compared to existing methods. This novel capability promises to enhance therapeutic precision, particularly in treating conditions like pain associated with pancreatic cancer—an area of critical need given the lack of reliable treatment options.
Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix, commended the selection of their abstract as a testament to the increasing clinical focus on precision nerve-targeted treatments. He emphasized that these early outcomes support the technology's potential across various applications where peripheral nerve signaling is pivotal.
The CRT conference serves as a premier educational platform for interventional cardiovascular medicine, with Top Abstract selections denoting the pinnacle of innovative research based on scientific merit and clinical relevance. Autonomix’s developments not only signify advances in neuromodulation technology but also herald a promising future for patient care in various medical fields, including cardiology and chronic pain management.
For more details, interested parties can visit Autonomix’s official website and follow the company on their social media platforms.
MWN-AI** Analysis
Autonomix Medical, Inc. (NASDAQ: AMIX) has garnered significant attention following its selection as the Top Abstract at CRT 2026, underscoring increasing interest in precision nerve-targeted therapies. This accolade, coinciding with the presentation of clinical data on their innovative transvascular RF neurolysis technique, positions Autonomix at a pivotal juncture within the medical device sector.
Investors should observe this development closely, as the novel technique promises to enhance clinical outcomes for conditions where peripheral nerve activity is critical, such as pain management in pancreatic cancer. Autonomix’s technology leverages a catheter-based sensing array that appears to offer superior detection and modulation of neural signals compared to traditional methods, potentially broadening therapeutic applications across multiple indications, notably cardiology and chronic pain management.
The clinical feasibility results presented by Dr. Nikola Cesarovic will provide further essential data. Positive early outcomes could validate the company's approaches, driving investor confidence. Nonetheless, it is crucial to remember that the technology is still investigational and not FDA-cleared, which introduces risk and uncertainty.
From a market perspective, this milestone could serve as a catalyst for Autonomix’s stock, particularly ahead of crucial clinical trial advancements or regulatory submissions. Investors may want to consider accumulating shares leading up to and following the presentation, with an eye on long-term potential as the company develops its product pipeline.
However, patience is advised, as the therapeutic landscape can be fraught with challenges despite promising initial results. Analysts should monitor subsequent data releases critically, especially regarding safety and efficacy outcomes, to gauge the sustainable impact on Autonomix’s valuation and stock performance moving forward. In summary, while Autonomix presents a compelling investment opportunity, the associated risks warrant a cautious approach.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC.
The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,” will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 - 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively disrupt peripheral nerve activity via a transvascular approach. Autonomix’s technology is engineered to identify and target specific nerve signals, potentially enabling differentiated therapeutic precision compared to conventional ablation techniques.
“This Top Abstract selection underscores the growing clinical interest in precision nerve-targeted therapies and highlights the potential of Autonomix’s platform to enable controlled, transvascular peripheral nerve modulation,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We believe these early feasibility findings support the broader applicability of our technology across multiple indications where peripheral nerve signaling plays a critical role.”
CRT is one of the world’s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ**
How does the innovation presented by Autonomix Medical Inc. (AMIX) in RF-based peripheral nerve neurolysis differentiate it from existing treatments currently available in the market?
What are the anticipated timelines for Autonomix Medical Inc. (AMIX) to seek FDA clearance for their investigational nerve-targeted treatments post the CRT 20meeting announcement?
Can you elaborate on how the technology of Autonomix Medical Inc. (AMIX) may expand beyond pancreatic cancer pain to address other indications involving peripheral nerve signaling?
What are the key risks and uncertainties associated with the forward-looking statements made by Autonomix Medical Inc. (AMIX) regarding their clinical feasibility findings and broader applications of their technology?
**MWN-AI FAQ is based on asking OpenAI questions about Autonomix Medical Inc. (NASDAQ: AMIX).
NASDAQ: AMIX
AMIX Trading
-2.46% G/L:
$0.4208 Last:
161,939 Volume:
$0.437 Open:
